Zacks: Brokerages Expect Savara Inc (NASDAQ:SVRA) Will Post Earnings of -$0.44 Per Share

Wall Street analysts expect Savara Inc (NASDAQ:SVRA) to announce earnings of ($0.44) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Savara’s earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.47). Savara reported earnings per share of ($0.37) during the same quarter last year, which suggests a negative year over year growth rate of 18.9%. The company is scheduled to report its next earnings report on Wednesday, November 6th.

On average, analysts expect that Savara will report full year earnings of ($1.70) per share for the current financial year, with EPS estimates ranging from ($1.82) to ($1.57). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.58) per share, with EPS estimates ranging from ($1.74) to ($1.28). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Savara.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, August 8th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05.

SVRA has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Savara from a “hold” rating to a “sell” rating in a report on Wednesday, October 16th. ValuEngine raised shares of Savara from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Evercore ISI set a $17.00 target price on shares of Savara and gave the company a “buy” rating in a report on Monday, August 12th. Finally, LADENBURG THALM/SH SH reaffirmed a “hold” rating and issued a $1.00 target price on shares of Savara in a report on Thursday, October 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. Savara currently has a consensus rating of “Hold” and an average target price of $9.09.

Shares of Savara stock remained flat at $$0.87 during trading on Monday. 1,823 shares of the stock were exchanged, compared to its average volume of 709,977. The stock has a fifty day moving average price of $2.00 and a 200-day moving average price of $5.22. The company has a market capitalization of $36.26 million, a price-to-earnings ratio of -0.67 and a beta of 0.20. Savara has a fifty-two week low of $0.82 and a fifty-two week high of $11.96. The company has a debt-to-equity ratio of 0.22, a quick ratio of 12.61 and a current ratio of 12.61.

Institutional investors and hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP acquired a new position in Savara in the 2nd quarter valued at $206,000. United Capital Financial Advisers LLC purchased a new stake in shares of Savara during the 2nd quarter worth $61,000. DekaBank Deutsche Girozentrale boosted its position in shares of Savara by 67.5% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the company’s stock worth $50,000 after purchasing an additional 8,300 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Savara by 43.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,475,000 shares of the company’s stock worth $8,236,000 after purchasing an additional 1,050,000 shares in the last quarter. Finally, Nomura Holdings Inc. purchased a new stake in shares of Savara during the 2nd quarter worth $496,000. 41.24% of the stock is currently owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Article: Profit margin is different from the revenue

Get a free copy of the Zacks research report on Savara (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.